
Pulse Biosciences (PLSE) Stock Forecast & Price Target
Pulse Biosciences (PLSE) Analyst Ratings
Bulls say
Pulse Biosciences is a bioelectric medicine company that is developing Nanosecond Pulsed Field Ablation technology for various medical treatments with potential for acquisition. The company has FDA clearance for their electrode system and is currently conducting a pivotal trial in the US, with potential risks including delays and competition. The market for AF treatment is expected to grow, giving potential for the company's technology to disrupt the market. However, risks such as disappointing clinical trial results and competition from larger companies should also be considered.
Bears say
Pulse Biosciences is expected to face several risks in the coming years, such as potential delays or disappointing data, despite being well-funded with enough cash to support operations until 2027, as analysts expect FDA approval for their new technology in late 2027 or early 2028. Though the company is actively pursuing partnerships and has a strong focus on research and development, their success is not guaranteed, making their current strong financial status a temporary advantage.
This aggregate rating is based on analysts' research of Pulse Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Pulse Biosciences (PLSE) Analyst Forecast & Price Prediction
Start investing in Pulse Biosciences (PLSE)
Order type
Buy in
Order amount
Est. shares
0 shares